Frank O'Brien
Lecturer in Urology
Honorary Consultant Urologist
Direct: +44 (0)1223 216344 email
NHS Secretary: +44 (0)1223 216068 email
Hinchingbrooke Secretary: Does not work at Hinchingbrooke
Special Interests: Kidney Cancer, nephron sparing surgery, renal function preservation, general urology
Recent Publications
Serum markers for prostate cancer: a rational approach to the literature
Steuber T, O'Brien MF, Lilja H
European Urology (2008), 54, 31-40
Prostate-specific antigen at or before age 50 as a predictor of advanced prostate cancer diagnosed up to 25 years later: a case control study
Ulmert D, Cronin AM, Bjork T, O'Brien MF, Scardino PT, Eastham JA et al
BMC Med (2008) 6, 6
Sunitinib therapy in renal cell carcinoma
O'Brien MF, Russo P, Motzer RJ
British Journal of Urology INternational (2008), 101, 1339-1342
Long-term prediction of prostate cancer: prostate-specific antigen (PSA) velocity is predictive but does not improve the predictive accuracy of a single PSA measurement 15 years or more before cancer diagnosis in a large, representative, unscreened population
Ulmert D, Serio AM, O'Brien MF, Becker C, Eastham JA, Scardino PT et al
Journal of Clinical Oncology (2008), 26, 835-841
Surgical intervention in patients with metastatic renal cancer: metastasectomy and cytoreductive nephrectomy
Russo P, O'Brien MF
Urologic Clinics of North America (2008), 35, 679-86
Can pre-assessment of patients with LUTS result in early discharge from urology clinic?
Dowling CM, O'Brien MF, Gardner S, Lennon G, Mulvin D, Quinlan DM
Irish Medical Journal (2008), 101, 203-204
Survival rates after resection for localized kidney cancer: 1989 to 2004
Russo P, Jang TL, Pettus JA, Huang WC, Eggener SE, O'Brien MF et al
Cancer (2008), 113, 84-96
The value of appropriate assessment prior to specialist referral in men with prostatic symptoms
Quinlan MR, O'Daly BJ, O'Brien MF, Gardner S, Lennon G, Mulvin DW et al
Irish Journal of Medical Science (2009), 178, 281-5
Editorial comment on: current applications for prostate-specific antigen doubling time
O'Brien MF
European Urology (2008), 54, 300-301
Systematic review of pretreatment prostate-specific antigen velocity and doubling time as predictors for prostate cancer
Vickers AJ, Savage C, O'Brien MF, Lilja H
Journal of Clinical Oncology (2009), 27, 398-403
Pretreatment prostate-specific antigen (PSA) velocity and doubling time are associated with outcome but neither improves prediction of outcome beyond pretreatment PSA alone in patients treated with radical prostatectomy
O'Brien MF, Cronin AM, Fearn PA, Smith B, Stasi J, Guillonneau B et al
Journal of Clinical Oncology (2009), 27, 3591-7
Prostate kallikrein markers in diagnosis, risk stratification and prognosis
Ulmert D, O'Brien MF, Bjartell AS, Lilja H
Nature Reviews in Urology (2009), 6, 384-91
The contribution of Irish urology to clinical practice
O'Brien MF, Galvin DJ, Mulhall JP
Urology (2009), 74, 972-8
All Consultants:
Tevita 'Aho, Andrew Doble, Vincent Gnanapragasam, Yasir Hassanein, Christof Kastner, John McLoughlin, David Neal, Frank O'Brien, Nimish Shah, Nikesh Thiruchelvam, Bill Turner, Oliver Wiseman
All Nursing Staff:
Shirley Bane, Gillian Basnett, Jo Burge, Wendy Campbell, Nicola Cheale, Carol Edmunds, Indu Francis, Sarah Harris, Claire Johnston, Sue Norman, Sandra Siddle, Sara Stearn, Mark Wynn
